Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2026-05-15 16:02:41 ET · period of report 2026-05-13 · accession 0001193125-26-226604 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 16:02 | 2026-05-13 | KPTI | Mano Michael | EVP, CLO, Sec | A - Grant | $0.00 | +700 | 94.7K | +0.7% | $0 | |
| 2026-05-15 16:02 | 2026-05-14 | KPTI | Mano Michael | EVP, CLO, Sec | S - Sale | $9.50 | -266 | 94.4K | -0.3% | -$2,527 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-13 | A | A | 700 | $0.00 | 94,664 | D | — | — | (F1) Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026. |
| 2 | Common | Common Stock | 2026-05-14 | S | D | 266 | $9.50 | 94,398 | D | — | — | (F2) This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person. |